Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

##STR00001##

An object of the present invention is to provide a kit, a method, and a reagent which prevent the problem of false positive due to nonspecific adsorption, suppress the increase in noise to be generated, and are capable of achieving high-precision measurement of a measurement target substance in a wide concentration range from a low concentration to a high concentration. According to the present invention, there is provided a kit for measuring a measurement target substance, the kit including: a first particle having a label and modified with a first binding substance; a second particle having no label and modified with a second binding substance; a flow channel for flowing the first particle and the second particle; and a substrate having a third binding substance capable of specifically binding to the measurement target substance or a substance capable of binding to the first binding substance, in which the first particle having a label is a luminescent labeled particle containing at least one kind of compound represented by Formula (1) and a particle. ##STR00001## Each symbol in Formula (1) has the meaning described in the present specification.

Biologically active compounds and their methods of preparation are provided that may be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of non-tumorous indications such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, otorhinolaryngology disorders, ophthalmological or urological disorders. As the compounds exhibit also toxicity against targets (tumor cells, bacteria, inflammation-related cells) without light these biologically active compounds may also be used for the light-independent treatment of such indications. Embodiments also include methods to synthesize boron dipyrromethene complex structures incorporating a substituted 2,3,5,6-tetrafluorophenyl-dipyrromethene (2,3,5,6-tetrafluorophenyldipyrrin) unit or a substituted 3-nitrophenyl-dipyrromethene (3-nitrophenyl-dipyrrin) unit. Amphiphilic compounds with increased anti-tumour and anti-bacterial efficacy are also provided. Specifically, this is achieved by substitution with bromine atoms and sugar moieties.

An organic electroluminescence device includes an anode, a cathode, and an emitting layer disposed between the anode and the cathode. The emitting layer comprises a delayed fluorescent compound M2 having at least one deuterium atom and a compound M3 having at least one deuterium atom. A singlet energy S.sub.1(M2) of the compound M2 and a singlet energy S.sub.1(M3) of the compound M3 satisfy the relationship S.sub.1(M3)>S.sub.1(M2).

The present application relates to substituted dyes containing bis-boron fused heterocycles and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

A battery pack including a first subset of battery cells and a second subset of battery cells, set of switches, a DC output port and an AC output port. The battery pack may provide both a DC output signal at the DC output port and an AC output signal at the AC output port by selectively activating the switches of the set of switches. The battery pack may couple the first subset of battery cells and the second subset of battery cells in a parallel configuration or a series configuration.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The present application relates to methods for treatment of bacteria and viruses with C.sub.2-C.sub.7 alkyl boronic acids to reduce growth and virulence.

The present disclosure relates to Near-infrared fluorescent indicators for lysosomes and application thereof. These indicators are composed of lipophilic NIR BODIPY derivatives and ionizable bis-tertiary amine moiety, which enable the formation of a transient amphiphilic state in acidic environments specifically. This structural feature affords accurate lysosomal membrane targeting ability at nanomole staining concentration.

The present specification relates to a nitrogen-containing compound, and a color conversion film, a backlight unit and a display apparatus including the same.